Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic Hepatitis B: Week 72 TDF data and week 24 Adefovir dipivoxil switch data (Study 102)
P Buggisch, M Manns, S Mauss, T Berg, G Teuber, WO Böcher, J Sorbel, J Anderson, E Mondou, J Quinn, F Rousseau, P Marcellin · Zeitschrift für Gastroenterologie · 2008 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: TDF, a nucleotide analogue and obligate chain terminator has potent activity against hepatitis B virus (HBV). Methods: Subjects with HBeAg- CHB mono-infection were randomized 2:1 to double-blind TDF (N=250) or ADV (N=125) for the first 48 weeks. After 48 weeks eligible subjects with week (WK) 48 biopsy were switched to TDF for up to an additional 4 years. HBV DNA was measured using the Roche COBAS TaqMan assay. Results: One hundred and twelve subjects originally randomized to ADV initiated TDF at WK48; 35 subjects had HBV DNA >400 c/mL just prior to switching to TDF. At WK72 after 24 weeks of TDF, 108/112…
